(Bloomberg) - A multibillion-dollar fight between the drug industry and antitrust enforcers is poised to get U.S. Supreme Court review in a case that may determine how quickly low-price generic medicines reach the market.

The justices will say as early as today whether they’ll scrutinize “pay for delay” agreements that the Federal Trade Commission says cost customers $3.5 billion each year.

Read more.